COSMOS Pharmaceutical Corporation (JP:3349)
:3349
Want to see JP:3349 full AI Analyst Report?
3349 Stock Chart & Stats
¥6699.00
¥109.00(1.60%)
At close: 4:00 PM EST
¥6699.00
¥109.00(1.60%)
Day’s Range― - ―
52-Week Range¥6,283.00 - ¥10,045.00
Previous CloseN/A
Volume659.40K
Average Volume (3M)399.89K
Market Cap
¥505.14B
Enterprise Value¥519.35B
Total Cash (Recent Filing)¥57.04B
Total Debt (Recent Filing)¥49.96B
Price to Earnings (P/E)17.0
Beta-0.24
Next Earnings
Jul 10, 2026EPS Estimate
117.37Next Dividend Ex-DateN/A
Dividend Yield0.93%
Share Statistics
EPS (TTM)102.19
Shares Outstanding80,001,600
10 Day Avg. Volume586,980
30 Day Avg. Volume399,893
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)2.72
Price to Sales (P/S)0.69
P/FCF Ratio-814.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)400.84
Revenue Forecast (FY)¥1.09T
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthCOSMOS shows multi-year revenue expansion (Fundamentals.RevenueGrowth ~6.74%), supporting scale in retail purchasing and store economics. Durable top-line growth in a consumer staples pharmacy model underpins predictable cash inflows and sustained market penetration over the medium term.
Stable Profitability & MarginsStable gross and net margins and healthy EBIT/EBITDA indicate effective cost management and merchandising mix discipline. For a drugstore retailer, sustained margins reflect pricing power in higher-margin categories and operational efficiency that support resilient earnings over 2–6 months and beyond.
Solid Balance Sheet And Low LeverageA low debt-to-equity ratio and strong equity ratio give the company financial flexibility to invest in stores, absorb demand shocks, and fund operations without excessive refinancing risk. This structural balance-sheet strength supports durable stability and strategic optionality.
Bears Say
Negative Free Cash Flow TrendPersistent negative free cash flow despite strong operating cash suggests cash conversion and capital intensity issues. Over the medium term this can constrain discretionary spending, increase reliance on external financing, and limit capacity to self-fund expansion or restore cash buffers.
Rising Total DebtAlthough leverage is currently low, the trend of rising total debt reduces the margin of safety and increases interest and refinancing risk. If continued, higher debt could erode financial flexibility and raise funding costs, undermining long-term resilience.
Pressure On EBIT MarginA declining EBIT margin signals cost pressures or margin mix shifts that could persist. For a retail pharmacy, sustained margin erosion would impair cash generation and profitability even with revenue growth, necessitating structural cost or merchandising changes to restore margins.
COSMOS Pharmaceutical Corporation News
3349 FAQ
What was COSMOS Pharmaceutical Corporation’s price range in the past 12 months?
COSMOS Pharmaceutical Corporation lowest stock price was ¥6283.00 and its highest was ¥10045.00 in the past 12 months.
What is COSMOS Pharmaceutical Corporation’s market cap?
COSMOS Pharmaceutical Corporation’s market cap is ¥505.14B.
When is COSMOS Pharmaceutical Corporation’s upcoming earnings report date?
COSMOS Pharmaceutical Corporation’s upcoming earnings report date is Jul 10, 2026 which is in 82 days.
How were COSMOS Pharmaceutical Corporation’s earnings last quarter?
COSMOS Pharmaceutical Corporation released its earnings results on Apr 13, 2026. The company reported ¥102.19 earnings per share for the quarter, beating the consensus estimate of ¥100.689 by ¥1.501.
Is COSMOS Pharmaceutical Corporation overvalued?
According to Wall Street analysts COSMOS Pharmaceutical Corporation’s price is currently Overvalued.
Does COSMOS Pharmaceutical Corporation pay dividends?
COSMOS Pharmaceutical Corporation pays a Semiannually dividend of ¥37.5 which represents an annual dividend yield of 0.93%. See more information on COSMOS Pharmaceutical Corporation dividends here
What is COSMOS Pharmaceutical Corporation’s EPS estimate?
COSMOS Pharmaceutical Corporation’s EPS estimate is 117.37.
How many shares outstanding does COSMOS Pharmaceutical Corporation have?
COSMOS Pharmaceutical Corporation has 80,001,600 shares outstanding.
What happened to COSMOS Pharmaceutical Corporation’s price movement after its last earnings report?
COSMOS Pharmaceutical Corporation reported an EPS of ¥102.19 in its last earnings report, beating expectations of ¥100.689. Following the earnings report the stock price went down -1.121%.
Which hedge fund is a major shareholder of COSMOS Pharmaceutical Corporation?
Currently, no hedge funds are holding shares in JP:3349
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMOS Pharmaceutical Corporation
COSMOS Pharmaceutical Corporation operates a chain of drug stores in Japan. It also operates 1,130 stores in the Kanto, Chubu, Kansai, Chugoku, Shikoku, and Kyushu regions. The company was founded in 1983 and is headquartered in Fukuoka, Japan.
Technical Analysis
Sundrug Co
―
Sugi Holdings Co
―
TSURUHA Holdings
―
Create SD Holdings Co., Ltd.
―
KUSURI NO AOKI HOLDINGS CO.,LTD.
―
Options Prices
Currently, No data available
---